Emerald Bioscience (EMBI) Stock Price, News & Analysis

Company Overview

Emerald Bioscience, Inc. (OTCMKTS: EMBI) is a life sciences company dedicated to the development, manufacturing and distribution of research reagents and diagnostic assay kits. The company’s offerings support applications in immunology, oncology and molecular biology, enabling academic institutions, contract research organizations (CROs) and pharmaceutical developers to advance preclinical research and clinical testing. Emerald Bioscience’s core mission is to accelerate scientific discovery by providing high-quality, reliable products that address evolving needs in biomarker analysis and therapeutic monitoring.

The company’s product portfolio includes enzyme-linked immunosorbent assay (ELISA) kits, multiplex immunoassays, monoclonal and polyclonal antibodies, recombinant proteins and nucleic acid detection reagents. In addition to off-the-shelf solutions, Emerald Bioscience offers custom assay development and validation services, supporting clients in designing bespoke assays for novel targets. Technical support and application development resources are provided through its in-house scientific team, ensuring seamless integration of Emerald’s products into complex research workflows.

Founded in 2005 and originally headquartered in Cambridge, Massachusetts, Emerald Bioscience expanded its operations in 2016 with the opening of a state-of-the-art R&D and manufacturing facility in San Diego, California. The company maintains a global distribution network serving customers across North America, Europe and the Asia-Pacific region. Through partnerships with strategic distributors and direct sales channels, Emerald Bioscience aims to strengthen its international footprint and support translational research initiatives worldwide.

Emerald Bioscience is led by President and Chief Executive Officer Dr. Laura Jensen, whose background in immunodiagnostics and molecular assay development has guided the company’s strategic growth. The senior leadership team also includes Chief Scientific Officer Dr. Michael O’Connor and Vice President of Business Development Maria Torres, each bringing extensive experience in life sciences commercialization. Together, they are focused on advancing Emerald’s pipeline of innovative products and expanding collaborative research efforts with academic and industry partners.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 6.96 million shs
• Average Volume: 14.24 million shs
• Market Capitalization: $24.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EMBI Stock Analysis - Frequently Asked Questions

How do I buy shares of Emerald Bioscience?

Shares of EMBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Emerald Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Emerald Bioscience investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Gold Resource (GORO), Meta Platforms (META), Heatwurx (PCSA), Akero Therapeutics (AKRO) and CymaBay Therapeutics (CBAY).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EMBI
• CIK: N/A
• Web: www.emeraldbio.life
• Phone: 949-336-3443
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $1.05 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -347.62%

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 3.59
• Quick Ratio: 3.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 268,074,000
• Free Float: N/A
• Market Cap: $24.13 million
• Optionable: Not Optionable
• Beta: 0.43